630 related articles for article (PubMed ID: 34538649)
1. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.
Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X
Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
4. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cell therapy for lung cancer: Potential and perspective.
Chen L; Chen F; Li J; Pu Y; Yang C; Wang Y; Lei Y; Huang Y
Thorac Cancer; 2022 Apr; 13(7):889-899. PubMed ID: 35289077
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Feldman L; Brown C; Badie B
Neuromolecular Med; 2022 Mar; 24(1):35-40. PubMed ID: 34665390
[TBL] [Abstract][Full Text] [Related]
7. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer.
Jin KT; Chen B; Liu YY; Lan HU; Yan JP
Cancer Cell Int; 2021 Feb; 21(1):83. PubMed ID: 33522929
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence.
Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
[TBL] [Abstract][Full Text] [Related]
10. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
Sutherland AR; Owens MN; Geyer CR
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
[TBL] [Abstract][Full Text] [Related]
11. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
12. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
14. The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells.
Gershovich PM; Karabelskii AV; Ulitin AB; Ivanov RA
Biochemistry (Mosc); 2019 Jul; 84(7):695-710. PubMed ID: 31509722
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]